Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...

Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The average one-year price target for Vor Biopharma (NasdaqGS:VOR) has been revised to $37.13 / share. This is a decrease of ...

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...

Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...

Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...

VOR pivoted from cell therapy to in-licensing telitacicept, securing $175M in private placement but at the cost of massive dilution. Telitacicept offers multi-billion market potential if global trials ...

BOSTON--(BUSINESS WIRE)--Vor Biopharma, an immuno-oncology company pioneering engineered hematopoietic stem cell (HSC) therapies for the treatment of hematological malignancies, today announced a $42 ...

Although VOR mostly focused on off-road motorcycles, it migrated to street bikes in 2002, the same year it changed its name to VOR Motorcycles. The VOR EN-E 530 is a big-bore four-stroke that ...

Vor Biopharma Inc. (NASDAQ:VOR), a biotechnology company focused on developing novel therapies for acute myeloid leukemia (AML), has recently announced a significant shift in its strategic direction.